GB2555270A - Autophagy-inhibiting compounds and uses thereof - Google Patents

Autophagy-inhibiting compounds and uses thereof Download PDF

Info

Publication number
GB2555270A
GB2555270A GB1718875.6A GB201718875A GB2555270A GB 2555270 A GB2555270 A GB 2555270A GB 201718875 A GB201718875 A GB 201718875A GB 2555270 A GB2555270 A GB 2555270A
Authority
GB
United Kingdom
Prior art keywords
autophagy
compound
inhibiting compounds
compounds
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB1718875.6A
Other versions
GB201718875D0 (en
Inventor
Deckwerth Thomas
Kleinman Edward
Ruan Fuqiang
Baker William
Klinghoffer Richard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Presage Biosciences Inc
Original Assignee
Presage Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Presage Biosciences Inc filed Critical Presage Biosciences Inc
Publication of GB201718875D0 publication Critical patent/GB201718875D0/en
Publication of GB2555270A publication Critical patent/GB2555270A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/40—Nitrogen atoms attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present disclosure describes a compound for use in the treatment of cancer, infectious disease, and autoimmune disorders. The compounds herein can inhibit autophagy in an affected cell to promote cell death. Further, the compound can be used to overcome the drug-resistance of certain cells.

Description

718875.6
27.05.2016
15.11.2017 (51) INT CL:
C07D 401/14 (2006.01) A61K 31/4725 (2006.01) A61P 35/00 (2006.01) C07D 215/40 (2006.01) C07D 403/14 (2006.01)
A61K 31/4709 (2006.01) A61K 31/517 (2006.01) C07D 215/38 (2006.01) C07D 401/12 (2006.01) C07D 405/14 (2006.01) (30) Priority Data:
(31) 62168291 (32) 29.05.2015 (33) US (31) 62304125 (32) 04.03.2016 (33) US (86) International Application Data:
PCT/US2016/034887 En 27.05.2016 (87) International Publication Data:
WO2016/196393 En 08.12.2016 (56) Documents Cited:
WO 2012/149186 A2 WO 2006/051489 A1 MCAFEE, Q. et al Autophagy inhibitor Lys05 has Single agent antitumor activity and reproduces the phenotype of a genetic autophagy deficiency 22/5/12 ZHANG, H. et al Synthesis and in vitro cytotoxicity evaluation of 4 amino quinoline derivatives biomedicine and Pharmacotherapy 24/5/2007 HEERDEN L.V. et al Synthesis and in vitro antimalarial activity of a series of bisquinoline and bispyrrolo [1,2a] quiinoxaline compounds 27/7/12 (71) Applicant(s):
Presage Biosciences Inc
530 Fairview Avenue North, Suite 1000, Seattle,
Washington, 98019, United States of America (58) Field of Search:
INT CLA61K, C07D
Other: eKOMPASS(KIPO internal), STN (Registry, Caplus), Google.
(72) Inventor(s):
Thomas Deckwerth Edward Kleinman Fuqiang Ruan William Baker Richard Klinghoffer (74) Agent and/or Address for Service:
Mewburn Ellis LLP
City Tower, 40 Basinghall Street, LONDON, Greater London, EC2V 5DE, United Kingdom

Claims (1)

  1. Title ofthe Invention: Autophagy-inhibiting compounds and uses thereof Abstract Title: Autophagy-inhibiting compounds and uses thereof (57) The present disclosure describes a compound for use in the treatment of cancer, infectious disease, and autoimmune disorders. The compounds herein can inhibit autophagy in an affected cell to promote cell death. Further, the compound can be used to overcome the drug-resistance of certain cells.
GB1718875.6A 2015-05-29 2016-05-27 Autophagy-inhibiting compounds and uses thereof Withdrawn GB2555270A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562168291P 2015-05-29 2015-05-29
US201662304125P 2016-03-04 2016-03-04
PCT/US2016/034887 WO2016196393A2 (en) 2015-05-29 2016-05-27 Autophagy-inhibiting compounds and uses thereof

Publications (2)

Publication Number Publication Date
GB201718875D0 GB201718875D0 (en) 2017-12-27
GB2555270A true GB2555270A (en) 2018-04-25

Family

ID=57441838

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1718875.6A Withdrawn GB2555270A (en) 2015-05-29 2016-05-27 Autophagy-inhibiting compounds and uses thereof

Country Status (2)

Country Link
GB (1) GB2555270A (en)
WO (1) WO2016196393A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3533451B1 (en) 2017-01-21 2022-07-27 Guangzhou Hanfang Pharmaceuticals Co., Ltd. Application of paeoniflorin-6'-o-benzene sulfonate in medicine for treating sjögren's syndrome
CA3154678A1 (en) * 2019-09-18 2021-03-25 The Regents Of The University Of California Biaminoquinolines and nanoformulations for cancer treatment
JP2023513793A (en) * 2020-02-14 2023-04-03 ソーク インスティテュート フォー バイオロジカル スタディーズ Macrocyclic ULK1/2 inhibitor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006051489A1 (en) * 2004-11-10 2006-05-18 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of 1,4-bis (3-aminoalkyl) piperazine derivatives in the treatment of neurodegenerative diseases
WO2012149186A2 (en) * 2011-04-29 2012-11-01 The Trustees Of The University Of Pennsylvania Novel bisaminoquinoline compounds, pharmaceutical compositions prepared therefrom and their use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006051489A1 (en) * 2004-11-10 2006-05-18 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of 1,4-bis (3-aminoalkyl) piperazine derivatives in the treatment of neurodegenerative diseases
WO2012149186A2 (en) * 2011-04-29 2012-11-01 The Trustees Of The University Of Pennsylvania Novel bisaminoquinoline compounds, pharmaceutical compositions prepared therefrom and their use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HEERDEN L.V. et al "Synthesis and in vitro antimalarial activity of a series of bisquinoline and bispyrrolo [1,2a] quiinoxaline compounds" 27/7/12 *
MCAFEE, Q. et al "Autophagy inhibitor Lys05 has Single agent antitumor activity and reproduces the phenotype of a genetic autophagy deficiency" 22/5/12 *
ZHANG, H. et al "Synthesis and in vitro cytotoxicity evaluation of 4 amino quinoline derivatives" biomedicine and Pharmacotherapy 24/5/2007 *

Also Published As

Publication number Publication date
WO2016196393A2 (en) 2016-12-08
WO2016196393A3 (en) 2017-05-18
GB201718875D0 (en) 2017-12-27

Similar Documents

Publication Publication Date Title
CY1119063T1 (en) SUBSTITUTED BICYCLE DYYDROPYRIMIDINONS AND THEIR USE AS SUSPENSIONS OF BACKGROUND ADJUSTMENT
EA201301353A1 (en) COMPOSITIONS AND METHODS OF OBTAINING PYRIMIDINE AND PYRIDINE COMPOUNDS WITH VTK INHIBITING ACTIVITY
RU2711869C3 (en) Imidazopyrrolopyrazine derivatives useful in the treatment of diseases caused by abnormal activity of Jak1, Jak3 or Syk protein kinases
EA201591906A1 (en) UREA DERIVATIVES USEFUL AS KINASE INHIBITORS
TN2015000355A1 (en) PYRROLO [2, 3-D] PYRIMIDINE DERIVATIVES AS JANUS-TYPE KINASE INHIBITORS (JAK)
EA201390821A1 (en) ANTAGONISTS OF LYSOPHPATIDIC ACID RECEPTORS AND THEIR APPLICATION
GB2555270A (en) Autophagy-inhibiting compounds and uses thereof
IL258297A (en) Dipeptide and tripeptide epoxy ketone protease inhibitors
EP3147285A3 (en) Purinone compounds as kinase inhibitors
EA201490912A1 (en) DERIVATIVES [1,2,3] TRIAZOLO [4,5-D] Pyrimidine as Agonists of Cannabinoid Receptor 2
EA201000797A1 (en) AMINOTRIAZOLES AS PI3K INHIBITORS
MX2014005766A (en) Uracil derivatives as axl and c-met kinase inhibitors.
EA201171454A1 (en) N- (GETERO) ARYLPYRROLIDINE DERIVATIVES PYRAZOL-4-ILPYRROLO [2,3-d] PYRIMIDINES AND PYRROL-3-ILPYRROLO [2,3-d] PYRIMIDINES AS AN INITIATORS YANUS-I-I-I-I-I-I-I-I-I-I-I-IU-ZY-3-d)
WO2006108075A3 (en) Compositions and methods for enhancing drug sensitivity and treating drug resistant infections an diseases
NZ721952A (en) Delayed release compositions of linaclotide
EA201200934A1 (en) ANTI-TRACT COMBINATIONS OF MEDICINES BASED ON ARTHEMISININE WITH OTHER CHEMOTHERAPEUTIC AGENTS
EA201491002A1 (en) DERIVATIVES [1,2,3] TRIAZOLO [4,5-D] Pyrimidine as Agonists of Cannabinoid Receptor 2
BR112012026174A2 (en) isolated antibody, isolated nucleic acid, vector, host cell, method of producing an antibody, immunoconjugate, pharmaceutical formulation, disease or dysfunction, antibody use, method of treatment, determination and separation
IN2015DN03751A (en)
ATE439347T1 (en) 7-(2H-PYRAZOLE-3-YL)-3,5-DIHYDROXY-HEPTANIC ACID DERIVATIVES AS HMG-CO-A-REDUCTASE INHIBITORS FOR THE TREATMENT OF LIPIDEMIA
WO2014186750A3 (en) Variants of tnfsf15 and dcr3 associated with crohn's disease
MX341728B (en) Sulfonamido derivatives of 3,4-diarylpyrazoles as protein kinase inhibitors.
GB2560109A (en) Monocyclic,thieno, pyrido and pyrrolo pyrimidine compounds and methods of use and manufacture of the same
WO2007047335A3 (en) Methods for use with baff antagonists
WO2009139886A3 (en) Targeting an hiv-1 nef-host cell kinase complex

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)